Hoth Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 6
- Market Cap
- $5M
- Introduction
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
- Conditions
- Xerosis CutisParonychiaAcneiform Eruption Due to Chemical
- Interventions
- Drug: HT-001 2% Topical GelDrug: HT-001 1% Topical GelDrug: HT-001 0.5% Topical GelDrug: HT-001 Placebo
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Hoth Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05639933
- Locations
- 🇺🇸
UCI Health - CIACC, Irvine, California, United States
🇺🇸UC Irvine - Chao Family Cancer Center, Orange, California, United States
🇺🇸The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Hoth Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04544943
- Locations
- 🇦🇺
Novatrials, Kotara, New South Wales, Australia